These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22239439)

  • 1. Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy.
    Tognon CE; Sorensen PH
    Expert Opin Ther Targets; 2012 Jan; 16(1):33-48. PubMed ID: 22239439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.
    Tognon CE; Somasiri AM; Evdokimova VE; Trigo G; Uy EE; Melnyk N; Carboni JM; Gottardis MM; Roskelley CD; Pollak M; Sorensen PH
    Cancer Res; 2011 Feb; 71(3):1060-70. PubMed ID: 21148487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer.
    Tao Y; Pinzi V; Bourhis J; Deutsch E
    Nat Clin Pract Oncol; 2007 Oct; 4(10):591-602. PubMed ID: 17898809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.
    Iams WT; Lovly CM
    Clin Cancer Res; 2015 Oct; 21(19):4270-7. PubMed ID: 26429980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the IGF1 axis in cancer proliferation.
    Bruchim I; Attias Z; Werner H
    Expert Opin Ther Targets; 2009 Oct; 13(10):1179-92. PubMed ID: 19663648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
    Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
    J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.
    Zhang H; Pelzer AM; Kiang DT; Yee D
    Cancer Res; 2007 Jan; 67(1):391-7. PubMed ID: 17210722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer.
    Haisa M
    J Int Med Res; 2013 Apr; 41(2):253-64. PubMed ID: 23569026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGF1R signalling and its inhibition.
    Riedemann J; Macaulay VM
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S33-43. PubMed ID: 17259557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors.
    Nagle AM; Levine KM; Tasdemir N; Scott JA; Burlbaugh K; Kehm J; Katz TA; Boone DN; Jacobsen BM; Atkinson JM; Oesterreich S; Lee AV
    Clin Cancer Res; 2018 Oct; 24(20):5165-5177. PubMed ID: 29941485
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting IGF-1 signaling pathways in gynecologic malignancies.
    Bruchim I; Werner H
    Expert Opin Ther Targets; 2013 Mar; 17(3):307-20. PubMed ID: 23294364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma.
    Ewing GP; Goff LW
    Clin Colorectal Cancer; 2010 Oct; 9(4):219-23. PubMed ID: 20920993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minireview: nuclear insulin and insulin-like growth factor-1 receptors: a novel paradigm in signal transduction.
    Sarfstein R; Werner H
    Endocrinology; 2013 May; 154(5):1672-9. PubMed ID: 23507573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Effects of Insulin and IGF1 Receptors on ERK and AKT Subcellular Distribution in Breast Cancer Cells.
    Sarfstein R; Nagaraj K; LeRoith D; Werner H
    Cells; 2019 Nov; 8(12):. PubMed ID: 31771180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin receptor and IGF1R are not required for oocyte growth, differentiation, and maturation in mice.
    Pitetti JL; Torre D; Conne B; Papaioannou MD; Cederroth CR; Xuan S; Kahn R; Parada LF; Vassalli JD; Efstratiadis A; Nef S
    Sex Dev; 2009; 3(5):264-72. PubMed ID: 19851056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy.
    Werner H; Sarfstein R; Bruchim I
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1101-1112. PubMed ID: 31731883
    [No Abstract]   [Full Text] [Related]  

  • 18. Type I insulin-like growth factor receptor as a therapeutic target in cancer.
    Miller BS; Yee D
    Cancer Res; 2005 Nov; 65(22):10123-7. PubMed ID: 16287993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
    Hartog H; Wesseling J; Boezen HM; van der Graaf WT
    Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.
    Hendrickson AW; Haluska P
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1032-40. PubMed ID: 19777391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.